Chronic lymphocytic leukemia and infection risk in the era of targeted therapies: Linking mechanisms with infections

Talal Hilal, Juan C. Gea-Banacloche, Jose F. Leis

Research output: Contribution to journalReview articlepeer-review

20 Scopus citations

Abstract

Chronic lymphocytic leukemia (CLL) is the most common adult leukemia in the world. Patient with CLL are at particular risk for infections due to inherent disease-related immune dysfunction in addition to the effect of certain systemic therapies on the immune system. The advent of B-cell receptor (BCR) inhibitors such as ibrutinib and idelalisib has led to a practice change that utilizes these targeted agents in the treatment of CLL, either in place of chemoimmunotherapy (CIT) or in later line settings. In this paper, we review the pathophysiology of immune dysfunction in CLL, the spectrum of immunodeficiency with the various therapeutic agents along with prevention strategies with a focus on targeted therapies.

Original languageEnglish (US)
Pages (from-to)387-399
Number of pages13
JournalBlood Reviews
Volume32
Issue number5
DOIs
StatePublished - Sep 2018

Keywords

  • CLL
  • Chronic lymphocytic leukemia
  • Ibrutinib
  • Idelalisib
  • Targeted therapy
  • Venetoclax

ASJC Scopus subject areas

  • Hematology
  • Oncology

Fingerprint

Dive into the research topics of 'Chronic lymphocytic leukemia and infection risk in the era of targeted therapies: Linking mechanisms with infections'. Together they form a unique fingerprint.

Cite this